Home › Targets › PD-1
PD-1 (8 companies · 24 programs)
Companies with an active program directed at PD-1.
- CR-001 — Non-Small Cell Lung Cancer Phase 1
- CR-001 — Hepatocellular Carcinoma Phase 1
- CR-001 — Biliary Tract Cancer Phase 1
- CR-001 — Gastric Cancer Phase 1
- CR-001 — Colorectal Cancer Phase 1
- CR-001 — Endometrial Carcinoma Phase 1
- CR-001 — Cervical Cancer Phase 1
- CR-001 — Ovarian Cancer Phase 1
- PH-762 — Cutaneous Squamous Cell Carcinoma Phase 1
- PH-762 — Melanoma Phase 1
- PH-762 — Merkel Cell Carcinoma Phase 1
- ivonescimab — Non-Small Cell Lung Cancer Phase 3
- ivonescimab — Colorectal Cancer Phase 3
- ivonescimab — Head and Neck Squamous Cell Carcinoma Phase 3
- rosnilimab — Rheumatoid Arthritis Phase 2
- Jemperli — Endometrial Cancer Approved
- zimberelimab — Clear Cell Renal Cell Carcinoma Phase 1
- zimberelimab
- Bria-IMT — Metastatic Breast Cancer Phase 3
- Bria-OTS — Metastatic Breast Cancer Phase 1
- LOQTORZI — Nasopharyngeal Carcinoma Approved
- LOQTORZI
- MDNA11 — Solid Tumors Phase 1
- MDNA223 Preclinical
